Triasima Portfolio Management inc. Has $6.40 Million Position in Medtronic PLC $MDT

Triasima Portfolio Management inc. grew its stake in shares of Medtronic PLC (NYSE:MDT) by 135.8% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 66,596 shares of the medical technology company’s stock after buying an additional 38,350 shares during the period. Triasima Portfolio Management inc.’s holdings in Medtronic were worth $6,397,000 as of its most recent filing with the SEC.

Other large investors have also made changes to their positions in the company. Corundum Trust Company INC acquired a new position in shares of Medtronic during the third quarter valued at about $27,000. Lodestone Wealth Management LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $27,000. Valley Wealth Managers Inc. acquired a new position in shares of Medtronic during the third quarter valued at about $29,000. Board of the Pension Protection Fund acquired a new position in shares of Medtronic during the fourth quarter valued at about $29,000. Finally, GoalVest Advisory LLC acquired a new position in shares of Medtronic during the fourth quarter valued at about $29,000. Institutional investors and hedge funds own 82.06% of the company’s stock.

Medtronic Stock Performance

NYSE MDT opened at $80.02 on Monday. The stock has a market cap of $102.74 billion, a P/E ratio of 22.29, a PEG ratio of 1.90 and a beta of 0.62. The company’s 50-day simple moving average is $88.44 and its 200 day simple moving average is $94.80. Medtronic PLC has a twelve month low of $78.91 and a twelve month high of $106.33. The company has a quick ratio of 1.87, a current ratio of 2.54 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, research analysts forecast that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s dividend payout ratio is currently 79.11%.

Wall Street Analyst Weigh In

MDT has been the topic of a number of analyst reports. Stifel Nicolaus lowered their target price on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating on the stock in a research note on Monday, April 6th. Needham & Company LLC reissued a “buy” rating and issued a $120.00 target price on shares of Medtronic in a research note on Thursday, March 26th. Truist Financial lowered their target price on shares of Medtronic from $103.00 to $95.00 and set a “hold” rating on the stock in a research note on Wednesday, April 15th. Jefferies Financial Group reissued a “hold” rating and issued a $95.00 target price on shares of Medtronic in a research note on Thursday, April 23rd. Finally, Wells Fargo & Company initiated coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an “overweight” rating and a $114.00 target price on the stock. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company. According to data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $107.80.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the sale, the executive vice president directly owned 32,768 shares of the company’s stock, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.26% of the company’s stock.

Key Headlines Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Received CE mark for the Stealth AXiS™ surgical system (spine & cranial); management frames the system as an integrated next‑generation navigation, planning and robotics platform that should help drive surgical growth and address hospital demand for consolidated systems. Medtronic plc (MDT) Receives the CE Mark for the Stealth AXiS™ Surgical System
• Positive Sentiment: CE mark in Europe for Stealth AXiS expands Medtronic’s addressable surgical market after earlier U.S. clearance — this supports the company’s surgical robotics/navigation growth story and creates new revenue opportunities in European hospitals. Medtronic’s Stealth AXiS Europe Approval Expands Surgical Growth Story
• Positive Sentiment: Progress on cardiac rhythm devices: Affera’s Sphere‑9 FDA Breakthrough designation and related CE activity for ablation catheters highlight Medtronic’s expanding pulsed‑field and RF ablation portfolio — could boost future electrophysiology revenue if trials and approvals continue to progress. Affera Breakthrough: FDA Nod For Sphere-9 Could Be A Game Changer For Medtronic (MDT)
• Positive Sentiment: FDA cleared a next‑generation mitral valve, and Medtronic has enrolled the first patient in a post‑approval study for the Altaviva tibial neuromodulation system — both items support incremental product revenue and clinical validation across cardiovascular and neuromodulation franchises. Medtronic wins FDA nod for next-gen mitral valve Medtronic enrolls first patient in post-approval study of Altaviva tibial neuromod
• Neutral Sentiment: Industry reports highlight wearable medical device market growth (Australia, Saudi Arabia) that could support long‑term opportunities for Medtronic’s wearable/remote monitoring initiatives, but these are broad market trends rather than company‑specific catalysts. Australia Wearable Medical Devices Market Trends and Forecasts Saudi Arabia Wearable Medical Devices Market Trends and Forecasts
• Neutral Sentiment: Competitor and sector moves — Masimo published a large real‑world study on pulse oximetry accuracy across skin tones; Teleflex named a new CEO; Orchestra BioMed received another FDA Breakthrough designation. These items influence competitive and regulatory context but are not direct Medtronic earnings drivers. Masimo SET Shows Accurate Pulse Oximetry in Newborns of All Skin Tones Teleflex Appoints Jason Weidman as President and CEO FDA Grants Orchestra BioMed Additional Breakthrough Device Designation for AVIM Therapy
• Negative Sentiment: Technical/market weakness: coverage noting MDT trading near multi‑month/1‑year lows highlights investor concern about valuation and near‑term momentum despite the product wins — this likely contributes to downward pressure on the stock. Medtronic Near Lows: S&P 500 Index Healthcare Story to Watch

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).